1. Home
  2. ANAB vs KARO Comparison

ANAB vs KARO Comparison

Compare ANAB & KARO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ANAB

AnaptysBio Inc.

HOLD

Current Price

$63.70

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Karooooo Ltd.

KARO

Karooooo Ltd.

HOLD

Current Price

$49.68

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANAB
KARO
Founded
2005
2001
Country
United States
Singapore
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
ANAB
KARO
Price
$63.70
$49.68
Analyst Decision
Buy
Strong Buy
Analyst Count
12
6
Target Price
$71.67
$59.33
AVG Volume (30 Days)
567.5K
55.6K
Earning Date
05-08-2026
05-15-2026
Dividend Yield
N/A
2.50%
EPS Growth
91.02
N/A
EPS
N/A
N/A
Revenue
$234,603,000.00
N/A
Revenue This Year
N/A
$22.17
Revenue Next Year
$52.14
$16.74
P/E Ratio
N/A
$24.13
Revenue Growth
157.01
N/A
52 Week Low
$17.11
$41.25
52 Week High
$73.30
$60.95

Technical Indicators

Market Signals
Indicator
ANAB
KARO
Relative Strength Index (RSI) 51.98 49.98
Support Level $53.46 $43.52
Resistance Level $69.56 $51.80
Average True Range (ATR) 5.32 2.13
MACD 0.01 -0.26
Stochastic Oscillator 64.47 16.03

Price Performance

Historical Comparison
ANAB
KARO

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About KARO Karooooo Ltd.

Karooooo Ltd is a provider of real-time mobility data analytics solutions for smart transportation. It offers a comprehensive, cloud-based smart mobility platform for connected vehicles and other assets. The company's software-as-a-service platform provides customers with differentiated insights and analytics to optimize business and workforce, increase efficiency and decrease costs, improve safety, monitor environmental impact, assist with regularity compliance, and manage risk. The segments of the group are Cartrack; Carzuka; and Karooooo Logistics, of which key revenue is derived from the Cartrack segment.

Share on Social Networks: